Oxford Biomarkers

Oxford Cancer Biomarkers

This company develops and commercialises precision diagnostic tests and digital pathology tools to help clinicians personalise cancer treatment and assess patient toxicity risks.

Persona-Dx

The company develops artificial intelligence biomarker tests for tissue and blood samples to help oncologists personalise cancer diagnosis and treatment for metastatic patients.

Asylia Diagnostics

This company develops an artificial intelligence platform to identify biomarkers and drug targets for precision immunotherapy for pharmaceutical and diagnostic firms.

Oxford Drug Design

This company develops novel cancer and antibiotic therapeutics for the healthcare industry using a proprietary artificial intelligence and machine learning drug discovery platform.

Celleron Therapeutics

This biopharmaceutical company develops precision medicine drugs and companion diagnostics for cancer patients to provide personalised oncology treatments.

Oncomark

This company develops prognostic tests for breast cancer patients to help clinicians determine the necessity of chemotherapy treatment.

OXCan

This company develops blood tests using proteomics and machine learning to enable early cancer detection for healthcare providers and patients.

Ataraxis AI

This company develops artificial intelligence models that predict cancer outcomes and treatment responses for healthcare providers and oncologists.